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Abstract
Background: Fetuses affected by placental insufficiency do not receive adequate nutrients and oxygenation,
become growth restricted and acidemic, and can demise. Preterm fetal growth restriction is a severe form of
placental insufficiency with a high risk of stillbirth. We set out to identify maternal circulating mRNA transcripts that
are differentially expressed in preterm pregnancies complicated by very severe placental insufficiency, in utero fetal
acidemia, and are at very high risk of stillbirth.
Methods: We performed a cohort study across six hospitals in Australia and New Zealand, prospectively collecting
blood from 128 pregnancies complicated by preterm fetal growth restriction (delivery < 34 weeks’ gestation) and 42
controls. RNA-sequencing was done on all samples to discover circulating mRNAs associated with preterm fetal
growth restriction and fetal acidemia in utero. We used RT-PCR to validate the associations between five lead
candidate biomarkers of placental insufficiency in an independent cohort from Europe (46 with preterm fetal
growth restriction) and in a third cohort of pregnancies ending in stillbirth.
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Results: In the Australia and New Zealand cohort, we identified five mRNAs that were highly differentially
expressed among pregnancies with preterm fetal growth restriction: NR4A2, EMP1, PGM5, SKIL, and UGT2B1.
Combining three yielded an area under the receiver operative curve (AUC) of 0.95. Circulating NR4A2 and RCBTB2 in
the maternal blood were dysregulated in the presence of fetal acidemia in utero. We validated the association
between preterm fetal growth restriction and circulating EMP1, NR4A2, and PGM5 mRNA in a cohort from Europe.
Combining EMP1 and PGM5 identified fetal growth restriction with an AUC of 0.92. Several of these genes were
differentially expressed in the presence of ultrasound parameters that reflect placental insufficiency. Circulating
NR4A2, EMP1, and RCBTB2 mRNA were differentially regulated in another cohort destined for stillbirth, compared to
ongoing pregnancies. EMP1 mRNA appeared to have the most consistent association with placental insufficiency in
all cohorts.
Conclusions: Measuring circulating mRNA offers potential as a test to identify pregnancies with severe placental
insufficiency and at very high risk of stillbirth. Circulating mRNA EMP1 may be promising as a biomarker of severe
placental insufficiency.
Keywords: Circulating mRNA, Pregnancy, Fetal growth restriction, Fetal hypoxia
Background
Preterm fetal growth restriction arises when there is
poor placental function at a preterm gestation. While
preterm fetal growth restriction (such as requiring deliv-
ery prior to 34 weeks’ gestation) is uncommon, affecting
0.2–0.5% of pregnancies, it is one of the most severe
complications of pregnancy. These fetuses are at high
risk of stillbirth [1] or major perinatal injury that leads
to permanent disability [2].
A slowing of growth that leads to preterm fetal growth
restriction occurs because the under-functioning pla-
centa cannot meet the nutrient and oxygen demands of
the fetus for normal growth velocity. If severe, it can
progress to fetal hypoxia and acidemia. The acidemia
arises from an accumulation of lactic acid, produced be-
cause the fetus switches to anaerobic metabolism in the
face of hypoxia. The lactic acid can cause asphyxial
neuronal and myocardial injury, culminating in stillbirth.
Given there are no therapies to rescue in utero placen-
tal insufficiency [3], the current clinical management for
preterm fetal growth restriction is to leave fetuses in
utero to gain gestation, but to deliver promptly if there
is evidence that the fetus is significantly acidemic.
Ultrasound-based tests or the cardiotocograph (to detect
ominous fetal heart rate patterns) are commonly used to
detect the presence of pre-terminal fetal hypoxia/acide-
mia [4]. These capture physiological changes that are as-
sociated with fetal hypoxia or acidemia [5] such as
increased resistance to blood flow in the uterine artery
(maternal compartment) or the umbilical artery (placen-
tal compartment) [6], decreased resistance in the fetal
middle cerebral artery (fetal compartment) [7], or the
presence of specific fetal heart rate patterns [8].
While these tests have improved outcomes including
perinatal survival, none of these existing tests can reli-
ably determine which pregnancies are affected by
significant fetal acidemia [8]. Even with the clinical avail-
ability of these tests, preterm growth-restricted fetuses
are still lost to stillbirth or suffer significant perinatal as-
phyxial injury [9]. We therefore need better clinical tests
to identify the presence of severe placental insufficiency
and to flag fetuses that are extremely compromised and
at imminent risk of stillbirth, or severe injury in utero
leading to permanent disability after birth.
Detecting biochemical/molecular changes in the pres-
ence of significant placental insufficiency and fetal hyp-
oxia may be a new strategy to monitor fetal wellbeing in
these high-risk pregnancies and could add precision to
existing clinical tests. RNAs are shed from many organs,
including the placenta [10], and released into the circu-
lation where they can be sampled and measured [11, 12].
Furthermore, there are numerous reports demonstrating
differential expression in the circulation of RNAs coding
various genes when there is significant pathology, such
as cancers [13, 14].
Circulating RNA concentrations of some genes vary
with such predictability across pregnancy that their ma-
ternal signature might be able to determine gestational
age with an accuracy comparable to ultrasound fetal
measurements [15]. It is also possible that circulating
RNAs could be used as novel clinical biomarkers of ob-
stetric disease. Most studies have explored their use in
the diagnosis or prediction of pregnancy complications
such as preeclampsia [16, 17] and spontaneous preterm
birth [15].
We propose a conceptually different use of circulating
RNAs: to monitor fetal wellbeing by identifying fetuses
with severe placental insufficiency and fetal acidemia
that are at high risk of stillbirth or neonatal morbidity.
Beside our small pilot study [18], the concept of measur-
ing circulating RNAs to monitor fetuses at risk of still-
birth has not been explored.
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Here we report a large multi-center cohort study
where maternal blood obtained just prior to delivery was
used to identify circulating RNAs that were associated
with preterm fetal growth restriction, fetal acidemia, and
stillbirth. We did mass RNA seq in one cohort, but not
all three cohorts. Hence the line, as originall written,
could be slightly misleading. differentially expressed with
disease. We then validated genes that were differentially
expressed in an independent cohort from a different
continent and in a third cohort of pregnancies that
ended in stillbirth from severe preterm fetal growth
restriction.
Methods
Study participants for our cohorts
Fetal Oxygenation (FOX) Study
We collected maternal blood samples from 128 women
with preterm growth-restricted fetuses.
Participants were recruited across five tertiary hospi-
tals in Australia: Mercy Hospital for Women, Heidelberg
(in Victoria); Royal Women’s Hospital, Parkville (in
Victoria); Sunshine Hospital, St Albans (in Victoria);
Mater Mothers Hospital, South Brisbane (Queensland);
Royal Hospital for Women, Randwick (New South
Wales); and Royal North Shore Hospital, St Leonards
(New South Wales). We also collected samples from a
sixth site, the National Women’s Health Auckland City
Hospital, Grafton, in New Zealand. Ethics approval was
obtained from all institutions (approval numbers: MHW
R11/04, RWH + Sunshine Hospital 10/41, MMH 1928
M, RHW 12/240, RNSH 1305-151M, NWH, ACH 12/
NTA/96/AM02), and all women provided written in-
formed consent.
Preterm fetal growth restriction was defined as a cus-
tomized birthweight < 10th centile (www.gestation.net,
Australian parameters) requiring iatrogenic delivery
prior to 34 weeks’ gestation with uteroplacental insuffi-
ciency (asymmetrical growth + abnormal artery Doppler
velocimetry +/− oligohydramnios +/− abnormal fetal
vessels velocimetry). We excluded fetal growth restric-
tion due to infection, chromosomal or congenital abnor-
malities, and multiple pregnancy.
All blood samples were collected within 2 h of birth by
cesarean section into PAXgene® Blood RNA tubes (Pre-
Analytix, Hombrechtikon, Switzerland) which are de-
signed for blood collection and storage of nucleic acids
for later extraction and quantification. We determined
the fetal hypoxic status in the preterm growth restriction
cohort by collecting umbilical cord artery blood from
the placenta at birth and measuring the pH, where hyp-
oxia was defined as pH < 7.2 and normoxia being pH >
7.2. The pH was measured using clinical grade assays
used in the maternity service at the different recruiting
hospitals.
We also collected blood into Paxgene tubes from 42
controls where samples were collected at 28 and 34
weeks’ gestation. All these pregnancies had appropriately
grown fetuses that progressed to birth at term. See
Table 1 for participant characteristics in the FOX
cohort.
Cohort of pregnant women who had paired blood samples
taken pre and post steroids
We recruited 16 participants presenting to Mercy Hos-
pital for Women and were administered 11.4-mg intra-
muscular dose of betamethasone. This injection is
offered as part of clinical management for pregnancies
where there is a risk of preterm birth occurring as it can
improve perinatal outcomes for fetuses who deliver
early. We obtained blood prior to the corticosteroid in-
jection and 24 h to examine whether betamethasone af-
fected the expression of circulating mRNAs. We
obtained written informed consent from participants.
Ethics approval was obtained for this study (R11/34).
EVERREST cohort
Maternal blood samples were collected from 46 women
carrying a severely growth-restricted preterm fetuses
(20 + 0 to 20 + 6 weeks’ gestation) from four sites in
Europe: 37 from the UK (University College London),
four from Germany (University Medical Centre,
Hamburg-Eppendorf), One from Spain (Maternal-Fetal
Unit Hospital Clinic, Barcelona), and four from Sweden
(Lund University Hospital and University Hospital
Malmö). Blood was collected in Paxgene tubes for later
analysis. The protocol for the EVERREST cohort has
been published and provides detailed methods regarding
the study [19]. The cases selected for this study were
from the biobank component of this prospective study.
Controls were either women undergoing termination
of pregnancy at preterm gestations for medical reasons
(n = 9), or healthy ongoing pregnancies where bloods
were taken preterm and they progressed to term gesta-
tion (n = 18). See Additional file 1: Table S1 for patient
characteristics.
Stillbirth study
Maternal blood samples were from six women carrying
a growth-restricted preterm fetus that ended in stillbirth
at either the Mercy Hospital for Women or the Royal
Women’s Hospital. For all cases, the fetuses were ex-
tremely small (or growth restricted) at a very preterm
gestation where the prognosis for the fetus was poor.
For all cases, a clinical decision was made (in consult-
ation with the mother) for conservative management ra-
ther than to deliver the pregnancy. Serial blood samples
were drawn until fetal demise was diagnosed. The pres-
ence of ongoing fetal cardiac activity was confirmed at
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the time of each blood sampling. Gestation matched
healthy controls were obtained at both hospitals from
pregnancies which resulted in a healthy liveborn neo-
nate. Bloods for both cohorts were collected into PAX
gene tubes for later RNA extraction and quantification.
See Additional file 1: Table S2 for clinical information
regarding this cohort.
Blood sample collection and storage
Maternal peripheral whole blood (2.5 ml) were collected
into PAXgene® Blood RNA tubes according to the man-
ufacturer’s instructions. After collection, tubes were gen-
tly inverted (~ 8 times), stored upright at room
temperature for between 24 and 72 h, frozen at − 20 °C
for 24–72 h and subsequently transferred to storage at
− 80 °C until extraction processing.
RNA extraction and preparation
Total RNA was extracted in batches at either at the
Mercy Hospital for Women (FOX study, corticosteroid
and stillbirth cohorts) or the University College London
(EVERREST study), using the PAXgene® Blood miRNA
Kit (Pre-Analytix, Hombrechtikon, Switzerland) accord-
ing to the manufacturer’s instructions. In brief, samples
were thawed and centrifuged and pellets washed and re-
suspended in buffer. Proteins were digested using pro-
teinase K, and cellular debris removed. The supernatant
of the resulting flow-through was collected and isopro-
panol added. Samples were then centrifuged through
PAXgene RNA spin columns, and genomic DNA con-
tamination was removed using DNAse digestion. Puri-
fied RNA was eluted, and the concentration of RNA was
determined by NanoDrop® ND-8000 8-sample spectro-
photometer (ThermoFischer Scientific, Waltham, USA).
Next-generation sequencing to identify mRNAs in the
maternal circulation
RNA-seq sample preparation and sequencing
RNA was quantified using the NanoDrop 1000 Spectro-
photometer (Thermo Scientific) and RNA integrity
Table 1 Patient characteristics for cases of preterm fetal growth restriction and control cohorts as part of the FOX study
Characteristics Preterm fetal Growth restriction (n = 128) Controls (n = 42) P
Maternal age, years 32 (6) 30 (6) 0.13
Nulliparity 80 (63%) 38 (45%) 0.013
Body-mass index, kg/m2 27 (6) 24 (5) 0.0009
Smoking during pregnancy 17 (13%) 6 (7%) 0.16
Diabetes during pregnancy 15 (12%) 8 (10%) 0.60
Chronic hypertension 12 (9%) 0 (0%) 0.004
Preeclampsia 63 (49%) 3 (4%) < 0.00001
Absent or reversed end diastolic flow in umbilical artery 58 (45%) – –
Median gestational age at blood sampling, weeks 30.5 (28.6–32.1) 30.0 (28–32.1) 0.21
Median gestational age at delivery, weeks 30.5 (28.6–32.1) 39.4 (39–40.2) < 0.00001
Birthweight, g 1023 (315) 3594 (480) < 0.00001
Median birthweight centiles, corrected for gestationa 0.1 (0.0–0.4)% 40.8 (27.9–60.9)% < 0.00001
Male sex 71 (55%) 46 (55%) 0.92
Median Umbilical pH 7.27 (7.22–7.3) –
Umbilical pH < 7.2 22 (17.2%) –
Composite of severe neonatal morbidityb 39 (30%) 0 (−) 0.0002
Neonatal death within 42 days of birth 2 (2%) 0 (−) 0.42
Required resuscitation at birthc 106 (84%) 4 (9.5%) < 0.0001
Median duration of stay in the neonatal intensive care unit (in days) 30 (10.8–61.5) 0 (0–0) < 0.0001
Respiratory distress syndrome 94 (73%) 2 (5%) < 0.0001
Required ventilation 86 (67%) 0 (−) < 0.0001
Data are n (%), mean (SD), or median (interquartile range). Comparison between preterm fetal growth restriction cases and controls (where bloods were taken
around the same gestational age) is by chi-squared analysis and t test. Each control contributed two blood samples for the analysis, at 28 and 32 weeks’ gestation.
This was done to correct for possible changes in RNA concentrations across gestational age
aWe used a fetal weight reference charts to determine centiles (Hadlock formula, except fetal sex was corrected for)
bComposite of severe neonatal morbidity includes intraventricular hemorrhage, periventricular leukomalacia, sepsis, necrotizing enterocolitis, seizures, or hypoxic
ischemic encephalopathy
cRequired resuscitation at birth which included any of the following: cardiopulmonary resuscitation, intubation, continuous positive airway pressure, and the
administration of adrenaline or surfactant
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assessed with the Agilent Bioanalyzer 2100 (Agilent
Technologies). Illumina’s TruSeq stranded RNA sample
preparation kit with globin depletion was used to pre-
pare libraries for sequencing, performed by the Austra-
lian Genome Research Facility (Parkville, Australia).
Libraries were pooled and clustered using the Illumina
cBot system, followed by sequencing on the Illumina
HiSeq 2000 platform to obtain 50 base pair single-end
reads.
Quality control and data pre-processing
The FastQC software [https://www.bioinformatics.babra-
ham.ac.uk/projects/fastqc/] was used to assess the qual-
ity of the raw sequence data. Sequences were then
mapped to the human reference genome (hg19, from the
GATK Resource Bundle https://gatk.broadinstitute.org/
hc/en-us/articles/360035890811-Resource-bundle) using
the Rsubread program [20], and gene-level counts were
obtained by the featureCounts procedure [21]. Further
analysis was undertaken using the edgeR [22] and limma
[23] R/Bioconductor packages. Counts per million
(CPM) were calculated for each gene to standardize for
differences in library-size, and filtering was carried out
to retain genes with a baseline expression level of at least
2 CPM in 2 or more samples. TMM normalization was
applied [24]. Multidimensional scaling (MDS) plots
based on the log2(CPM) were generated to show rela-
tionships between samples based on case status (cases of
preterm fetal growth restriction or controls), the hospital
where samples were collected (to examine the possibility
of batch variability), and fetal sex and to check for the
presence of outliers.
Differential expression analysis
Voom was used to transform the count data to
log2CPM, estimate the mean-variance relationship, and
compute appropriate observation-level weights. A linear
model [25] was then fitted to this data, including a coef-
ficient for the case vs controls difference. Moderated t-
statistics were used to assess differential expression
between case and control samples, with genes ranked ac-
cording to their false discovery rate [26].
Table 2 Circulating mRNAs that were differentially expressed in the maternal blood of prospective FOX cohort preterm fetal growth
restriction vs healthy pregnancies identified by RNA-seq and linear regression analysis
Entrez ID Gene symbol logFC Average expression P Adjusted P* Selected for
RT-PCR validation**
100462977 MTRNR2L1 − 2.26 3.71 4.55E−16 1.95E−12
8460 TPST1 1.39 4.43 3.90E−19 4.38E−15 Y
9509 ADAMTS2 2.99 0.36 6.09E−11 2.36E−08 Y
100505479 NA − 1.98 1.34 2.25E−12 2.02E−09
23500 DAAM2 2.35 2.11 2.21E−11 1.13E−08 Y
144535 CFAP54 1.33 1.67 5.21E−16 1.9E−12
4549 RNR1 − 1.89 8.60 1.34E−11 7.66E−09
4550 RNR2 − 1.60 11.06 3.50E−11 1.48E−08
100463486 MTRNR2L8 − 1.51 5.15 1.26E−11 7.42E−09 Y
100462981 MTRNR2L2 − 1.26 2.47 1.17E−13 1.88E−10
100505635 LOC100505635 2.16 − 0.12 3.77E−09 7.28E−07
4929 NR4A2 1.37 0.24 5.65E−12 3.96E−09 Y
10720 UGT2B11 − 1.37 0.53 1.09E−11 6.78E−09 Y
1831 TSC22D3 0.86 8.68 3.21E−22 7.21E−18 Y
2012 EMP1 1.24 0.65 2.51E−12 2.09E−09 Y
246 ALOX15 − 1.38 1.20 1.03E−10 3.71E−08 Y
100463488 MTRNR2L10 − 1.47 − 0.34 9.47E−10 2.35E−07 Y
55301 OLAH 2.07 0.41 8.43E−08 9.38E−06 Y
11251 PTGDR2 − 0.99 2.17 2.39E−14 4.87E−11 Y
25790 CFAP45 0.99 2.82 3.48E−14 6.51E−11
5239 PGM5 1.24 1.67 1.62E−10 5.44E−08 Y
Entrez ID Entrez gene identifier, logFC log2 fold-change, AveExpr average expression, or the A value, Y Yes. *Adjusted P value corrected for the false discovery rate.
**For RT-PCR validation, we selected these 13 genes because Taqman primer assays were available. The remaining eight genes we did not measure did not have
Taqman primers available
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Bioinformatic analysis of sequencing data
Linear regression analysis identified 21 genes (or pseu-
dogenes) that were differentially expressed, after adjust-
ing for multiple comparisons (Table 2). The switchBox
package from Bioconductor was used to train and valid-
ate a K-Top-scoring Pair classifier (KTSP). The KTSP al-
gorithm is a simple binary classifier based on the
ordering of two measurements, where the predictions
are based on the gene expression data [27]. A classifier
was trained using the default filtering function based on
the Wilcoxon test, and the top scoring pairs were ex-
tracted. This switchBox analysis identified a further two
genes that were differentially expressed (RCBTB2 and
SKIL).
Validation with quantitative real-time reverse-
transcription polymerase chain reaction (qPCR)
Total RNA was converted to cDNA using Applied Bio-
systems high capacity cDNA reverse transcriptase kit
(Thermofisher). Quantitative real-time reverse-
transcription polymerase chain reaction (qPCR) valid-
ation was carried out for 15 of the 23 genes identified in
the NGS analysis (genes assessed were RCBTB2 and
SKIL which were identified from the switchBox analysis,
and 13 out of 21 genes from the regression analysis and
these are listed on Table 2) using specific FAM-labeled
Taqman primer assays and universal PCR master mix
(Thermofisher) on the CFX 384 (Bio-Rad, Hercules, CA)
with the following run conditions: 50 °C for 2 min, 95 °C
for 10 min, 95 °C for 15 s, and 60 °C for 1 min (40 cycles).
GUSB, YWHAZ, and B2M were used as reference house-
keeping genes after validating that their expressions were
not altered across samples (collection timing, location,
and extraction). The comparative ΔΔCT method of ana-
lysis was used to determine relative expression. A CT
value over 35 cycles was used as a threshold to deem the
transcript as undetectable.
Statistical analysis of qPCR data and clinical baseline
characteristics
To compare baseline clinical characteristics of continu-
ous data, either Student’s T test (normally distributed)
or the Mann-Whitney test (not normally distributed)
was used. Chi-squared test was used to compare cat-
egorical data.
For the qPCR results, data was tested for normal dis-
tribution and statistically analyzed as appropriate. When
three or more groups were compared, the 1-way
ANOVA (for parametric data) or Kruskal-Wallis test
(for non-parametric data) was used. When two groups
were compared, either Student’s T test or the Mann-
Whitney test was used. All qPCR data is expressed as
mean ± SEM. P < 0.05 was considered significant.
To combine data from RNAs to develop potential
multi-marker tests, multivariate logistic modeling was
performed and discrimination assessed using area under
ROC curves and the sensitivity generated by setting spe-
cificity at around 90% (where it equates to a 10% screen
positive rate).
Statistical software used was Stata v15 (StataCorp.
2017. Stata Statistical Software: Release 15. College Sta-
tion, TX: StataCorp LLC) or Graphpad Prism 7 (Graph-
Pad Software, LA Jolla, CA).
Results
FOX study: prospective study of pregnancies complicated
by preterm fetal growth restriction
We performed a multi-center prospective cohort study
of 128 participants with pregnancies complicated by pre-
term fetal growth restriction across six major tertiary re-
ferral hospital across Australia and New Zealand (Fetal
Oxygenation (FOX) study). Table 1 provides the baseline
clinical characteristics of study participants in the FOX
study and shows that the preterm fetal growth restric-
tion cohort had significantly poorer neonatal outcomes
compared to controls.
All participants had an ultrasound examination where
the estimated fetal weight (EFW) was < 10th centile cor-
rected for gestation. They all subsequently gave birth by
cesarean section < 34 weeks’ gestation between 25 (+ 2
days) and 34 (+ 0 days) weeks where the decision for iat-
rogenic delivery was triggered by concerns regarding
fetal wellbeing. For all these cases of preterm fetal
growth restriction, we obtained maternal whole blood
within 2 h prior to birth. In fact, most of the cases were
very significantly growth restricted with a median birth-
weight centile (using intrauterine fetal charts [28]) of
only 0.1 (interquartile range 0.0–0.4), well below the
10th centile.
Blood samples were also collected from 42 controls
which were normal pregnancies where samples were
taken at similar gestations as those obtained from the
preterm fetal growth-restricted cohort. Given they were
healthy pregnancies, the control cohort were not deliv-
ered around the time of blood collection but, instead,
progressed uneventfully to term delivery (> 37 weeks’
gestation).
RNA-seq to identify circulating RNA transcripts that are
differentially regulated with severe preterm fetal growth
restriction
We performed RNA-seq on RNA isolated from whole
blood from the FOX cohort study participants. Bioinfor-
matic linear regression analysis identified 21 genes or
pseudogenes that were differentially expressed between
those with preterm fetal growth restriction and controls
(Table 2). We also performed a switchBox analysis
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which identified a further two genes, RCBTB2 and SKIL.
We performed a technical validation of 15 of the 23
genes identified by the RNA-seq analysis using quantita-
tive RT-PCR (13 selected from Table 2 and the two
identified by the switchBox analysis) and confirmed dra-
matic differences in expression for 13 of these genes
(Fig. 1a–e and Additional file 1: Fig. S1). Of two genes
identified as differentially expressed in the RNA-seq ana-
lysis that we selected for PCR validation, MTRNR2L8
was not significantly different and MTRNR2L10 had ei-
ther low or undetectable levels of expression in most
samples (data not shown).
Corticosteroids are routinely administered to the
mother prior to a planned birth before 34 weeks as this
substantially improves perinatal survival and neonatal
outcomes [29]. Given all those (except one) in the pre-
term fetal growth restriction cohort were exposed to
antenatal corticosteroids but none of the controls were,
we were concerned that the exposure to corticosteroids
might explain the differences seen in circulating RNA.
Therefore, we collected paired blood just prior to, and
24 h after a corticosteroid injection from 16 pregnant
women. This group was separate to the FOX study. Of
the 13 genes that were differentially expressed in the
blood of women with preterm growth restriction by
qRT-PCR, the five shown in Fig. 1 (NR4A2, EMP1,
PGM5, SKIL, and UGT2B1) were not affected by cor-
ticosteroid administration (Additional file 1: Fig. S2),
while the eight genes shown in Fig. S1 were changed
by the administration of corticosteroids (the effects of
corticosteroids on these eight genes are shown in
Additional file 1: Fig. S3).
Using the qRT-PCR findings for the five genes not af-
fected by corticosteroid administration, we performed
Fig. 1 Expression of circulating mRNAs among pregnancies with preterm fetal growth restriction in the FOX cohort. a–e qRT-PCR expression of
five genes identified by RNA-seq, and the receiver operating characteristic curves. Controls were ongoing pregnancies unaffected by growth
restriction where bloods were collected around the same gestational ages. f The receiver operating characteristic curve for detecting preterm
fetal growth restriction when these circulating genes were combined as a potential diagnostic test. FGR, fetal growth restriction. ****p < 0.0001.
Error bars are mean ± SEM
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multivariable logistic regression to develop a multi-
marker screening test for preterm fetal growth restric-
tion. This yielded a potential clinical test with an area
under the receiver operating characteristic (ROC) curve
of 0.95 (Fig. 1f). At a specificity of 90.9% (i.e., a 10%
screen positive rate), the test had 87.6% sensitivity in
identifying preterm fetal growth restriction, with a posi-
tive likelihood ratio of 9.6. When 10-fold cross validation
was applied to correct for overfitting, the ROC was 0.94
and the sensitivity was 72% at a similar specificity of
90.2%.
Forty-nine percent of the cases of preterm fetal growth
restriction had co-existent preeclampsia in the FOX co-
hort (Table 1). To confirm the fact that these five genes
remained differentially expressed in the absence of pre-
eclampsia, we split the cases into two groups; those with
and without co-existent preeclampsia and compared
them to controls. We confirmed that all five genes
remained differentially expressed in pregnancies with
preterm fetal growth restriction whether or not there
was co-existent preeclampsia (Additional file 1: Fig. S4).
Hence, by applying RNA-seq on a large cohort, we
have identified 13 genes that are differentially expressed
in the circulation in pregnancies complicated by preterm
fetal growth restriction. Among these, circulating RNA
transcripts of five genes were not affected by maternal
corticosteroid administration: NR4A2, EMP1, PGM5,
SKIL, and UGT2B1. Combining these biomarkers gener-
ated potential tests with strong diagnostic performance
to detect the presence of early preterm fetal growth re-
striction, although they would need to be validated in
further studies.
Validating the association between circulating RNA
coding NR4A2, EMP1, PGM5, SKIL, and UGT2B1 and
preterm fetal growth restriction
We next set out to validate the association between the
five genes unaffected by maternal corticosteroid admin-
istration and preterm fetal growth restriction in the
EVERREST cohort from Europe [19]. The samples inves-
tigated were the first samples collected from 46 partici-
pants soon after the initial diagnosis of preterm fetal
growth restriction (EFW < 3rd centile, median gesta-
tional age of sample collection was 23 + 1 weeks of gesta-
tion (interquartile range (IQR) 22 + 2 to 24 + 4 weeks’
gestation)). Controls were fetuses that were appropri-
ately grown for gestational age (Additional file 1: Table
S1 shows the clinical characteristics of the EVERREST
cohort). All samples in the EVERREST cohort were col-
lected prior to the administration of antenatal corticoste-
roids and were therefore not exposed to this drug, and
neither were any of the controls.
RT-PCR analysis confirmed that the mRNA expression
of NR4A2 and EMP1 were significantly increased with
preterm fetal growth restriction (Fig. 2a and b) and
PGM5 expression trended towards an increase (p = 0.06,
Fig. 2c). UGT2B1 (Fig. 2d) and SKIL was not differen-
tially expressed (Fig. 2e).
The association between EMP1 and preterm fetal
growth restriction appeared strongest. In this validation
cohort, circulating EMP1 as a lone marker had 65% sen-
sitivity in identifying the presence of preterm fetal
growth restriction at 90% specificity, and an AUC of
0.89 (95% CI 0.82–0.97; Fig. 2f). Combining EMP1 and
PGM5 had 72% sensitivity to detect preterm fetal growth
restriction at 90% specificity, and an AUC of 0.92 (95%
CI 0.86–0.98, Fig. 2g).
Thus, we have validated the association between pre-
term fetal growth restriction and increased circulating
mRNA coding NR4A2 and EMP1 (and possibly PGM5)
in an independent cohort of samples from another
continent.
Identifying circulating transcripts that are associated with
in utero fetal acidemia among fetuses that are growth
restricted in the FOX cohort
A clinical test that can identify preterm growth-
restricted fetuses at high risk of acidemia in utero and
requiring urgent delivery could be useful to monitor
fetal wellbeing. We examined the association between
mRNA concentrations of the 13 genes we identified as
differentially expressed in the blood of women with pre-
term growth-restricted pregnancies (shown in Fig. 1 and
Additional file 1: Fig. S1) with the umbilical artery pH
levels at the time of birth in the FOX cohort.
For all of the cases of preterm fetal growth restriction
in the FOX cohort, the maternal blood was collected
within 2 h prior to birth, and the umbilical artery pH
was sampled shortly after birth. The umbilical artery
blood was obtained from the umbilical cord (attached to
the delivered placenta) at birth. The umbilical artery pH
reflects the acidemic status of the fetus during its last
moments prior to birth and is widely used clinically as a
gold standard to retrospectively determine the true de-
gree of fetal acidemia in utero [30]. We did not restrict
this analysis to the five genes unaffected by corticoste-
roids given the entire cohort in this analysis (except one)
was exposed to this medication.
We defined fetal acidemia as an umbilical artery blood
pH < 7.2 given this is associated with a 4.2-fold increased
risk of perinatal death (compared to those born with a
pH > 7.2) [9] and is therefore a clinically significant
threshold. Of the 128 cases of preterm growth restric-
tion, 22 (17.2%) had a pH < 7.2. Figure 3a shows the
spread of umbilical cord pH among the preterm fetal
growth restriction cohort.
Of the 13 genes, circulating mRNA coding NR4A2
(Fig. 3b) and RCBTB2 (Fig. 3c) were differentially
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expressed among growth-restricted fetuses that were
acidemic at birth. PTGDR3 (Fig. 3d) trended towards a
reduction (p = 0.07). Combining the mRNA expression
of these three genes generated a multi-marker test with
an AUC of 0.74. Thus, we have identified a panel of cir-
culating mRNA transcripts that are associated with the
presence of significant fetal acidemia in utero.
Correlating circulating mRNA transcripts and the degree
of placental insufficiency in the EVERREST cohort
To obtain further evidence that circulating mRNAs may
be associated with clinical parameters that reflect fetal
wellbeing, we correlated the circulating mRNAs with
pathological Doppler ultrasound features of placental in-
sufficiency: increased blood flow resistance in the uterine
and umbilical arteries, and decreased resistance in the
fetal middle cerebral arteries. We performed this study
using the EVERREST cohort where the samples were
collected soon after the diagnosis of preterm fetal
growth restriction and prior to steroid administration.
We measured three of the most promising candidates by
PCR: NR4A2, RCBTB2 since they were differentially
expressed with fetal acidemia in the FOX cohort, and
EMP1 given its particularly strong association with fetal
growth restriction in both the FOX (Fig. 1b) and
EVERREST cohorts (Fig. 2b, f).
Of the three, circulating EMP1 (Fig. 4a) and RCBTB2
(Fig. 4b) was significantly changed with raised uterine ar-
tery blood flow resistance. EMP1 (Fig. 4c) was associated
with increased umbilical artery Doppler blood flow re-
sistance, but RCBTB2 and NR4A2 were not (not shown).
However, RCBTB2 (Fig. 4d) and NR4A2 (Fig. 4e) were
associated with decreased middle cerebral artery
resistance.
Finally, we examined the prognostic ability of the cir-
culating transcripts from the first blood sample obtained
soon after diagnosis (taken between 20 + 0 to 26 + 0
weeks’ gestation) to predict which pregnancies will pro-
gress to term gestation (which implies the presence of a
less severe form of placental insufficiency at the time of
blood sampling that is also not progressive) versus those
that required preterm delivery due to concerns of deteri-
orating fetal status. We did this by examining those re-
cruited to the EVERREST study and grouping the cohort
according to whether they progressed to term gestation
(> 37 weeks’ gestation) or not. EMP1 (Fig. 4f) was
significantly increased among those destined for preterm
birth, and RCBTB2 was significantly decreased (Fig. 4g).
Thus, we have shown circulating mRNAs that are as-
sociated with clinically accepted parameters of placental
insufficiency. EMP1 appears to consistently demonstrate
the strongest association.
Identifying circulating transcripts that are associated with
subsequent stillbirth
We next measured the 13 gene transcripts in blood that
we identified as differentially expressed in association
with preterm fetal growth restriction among six cases
that ended in stillbirth (Additional file 1: Table S2 shows
the clinical characteristics). These were pregnancies
where it was clinically apparent that growth restriction
was exceptionally severe. In these cases, the prognosis
was deemed exceptionally poor because the fetus was
both extremely growth restricted and preterm, and thus
on the threshold of viability. In all cases, a clinical deci-
sion was made with the parents not to deliver the fetuses
but instead proceed with expectant management in the
hope of gaining a meaningful increase in gestation. None
received antenatal corticosteroids. All fetuses were con-
firmed to be live at the time of sample collection, evi-
denced by the presence of fetal cardiac activity. Controls
were healthy, ongoing pregnancies.
We first examined the final bloods taken prior to fetal
demise. Of the 13 genes, circulating mRNA coding
EMP1 (Fig. 5a), NR4A2 (Fig. 5b) and RCBTB2 (Fig. 5c)
were significantly altered in the stillbirth cohort com-
pared to controls. The differences appeared particularly
strong for EMP1 where five of six cases had mRNA ex-
pression levels higher than all controls.
We then examined the expression of these three genes
in all serial blood samples taken prior to demise in the
same population and found that expression levels
seemed to be consistently higher than the median levels
in the control group (Fig. 5d–f).
Discussion
By performing RNA-seq on samples from a large multi-
center cohort study, we have identified numerous circu-
lating mRNA that were very significantly deranged in
the circulation of pregnancies complicated by early pre-
term fetal growth restriction. Importantly, we have also
obtained evidence that the relative concentrations of
mRNAs of some genes, notably EMP1, correlated with
(See figure on previous page.)
Fig. 2 Expression of circulating mRNAs among 46 pregnancies with preterm fetal growth restriction in the EVERREST cohort vs 27 appropriately
grown fetuses. a–e Expression levels of five circulating RNAs that were discovered in the FOX cohort. For PGM5 p = 0.06. f The receiver operating
characteristic curve for EMP1 to detect fetal growth restriction. g The receiver operating characteristic curve when EMP1 and PMG5 are combined
to detect fetal growth restriction. **p < 0.004. ****p < 0.0001. Error bars are mean ± SEM
Hannan et al. BMC Medicine          (2020) 18:145 Page 10 of 16
many clinical parameters that reflect severity of placental
dysfunction and the likely presence of in utero fetal acid-
emia [9]. These include umbilical cord artery pH at
birth, and Doppler waveform velocimetry of the uterine,
umbilical artery, and middle cerebral arteries. Further-
more, we have also identified circulating mRNAs that
were deranged in a small cohort of pregnancies destined
for stillbirth. Together, our work suggests that circulat-
ing mRNAs could be used to monitor fetal health dy-
namically over time and to identify fetuses with very
severe placental insufficiency and at high risk of
imminent stillbirth. It is possible that a circulating
mRNA-based test could be developed that allows clini-
cians to deliver severely compromised fetuses before
Fig. 3 The association between circulating mRNAs in the maternal circulation and fetal acidemia. Those with preterm fetal growth restriction in
the FOX study were examined. Maternal bloods were taken within 2 h of birth and fetal pH (pH < 7.2 is defined as fetal acidemia) taken from the
umbilical artery shortly after birth. a The spread of umbilical artery pH concentrations in the FOX cohort. Red dot is the median value. b–d
Expression levels of three circulating RNAs. For PTGDR2 p = 0.07. e The receiver operated curve when circulating NRA2, RCBTB2, and PTGDR2 in the
maternal circulation are combined to detect fetal acidemia (pH < 7.2). The area under the receiver operated curve (AUC) was 0.74 (95% CI
0.59–0.89). *p < 0.05
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demise, maximizing gestation yet preventing cases of
stillbirth.
Of all the circulating mRNA molecules we identified,
EMP1 appears the most promising as a marker of pla-
cental insufficiency. Even as a lone marker, it seems to
have strong discriminatory ability to identify the pres-
ence of early preterm fetal growth restriction, a finding
that we validated in the EVERREST cohort from Europe
[19]. Furthermore, EMP1 was correlated with severe clin-
ical parameters that reflect placental insufficiency and was
deranged in another cohort of women with preterm fetal
growth restriction whose pregnancies ended in stillbirth.
Circulating EMP1 (and perhaps RCBTB2) merit further
study to determine whether they can add to the diagnostic
accuracy of ultrasound to monitor fetal health.
There is little known about the five genes we identified as
differentially regulated in association with placental insuffi-
ciency (Additional file 1: Table S3 summarizes the postulated
biological functions of the protein products coded by
NR4A2, EMP1, PGM5, SKIL, and UGT2B1mRNAs).
While the concept of measuring circulating molecules (in-
cluding mRNA) to predict pregnancy complications has
been around for over a decade [16], the idea of measuring
mRNA to monitor fetal health and placental insufficiency to
prevent stillbirth is novel. Indeed, none of the circulating
mRNA markers we report here have been previously re-
ported to be associated with placental insufficiency.
In 2016, a consortium published the Delphi definition
for fetal growth restriction [31]. The reason why we did
not use this definition for the FOX cohort is that the de-
sign of the FOX study predated this publication. However,
for our growth restriction cohort, the birthweight centiles
of cases were mostly below < 3rd centile and had ultra-
sound findings that triggered birth. On reviewing the clin-
ical information on the cohort, 97% (124 out of the 128
cases) fulfilled the Delphi criteria for fetal growth restric-
tion. All the cases of preterm growth restriction in the
EVERREST study fulfilled the Delphi definition for fetal
growth restriction.
Our work has a number of strengths. Preterm fetal growth
restriction represents one of the most dangerous complica-
tions of pregnancy for the fetus but is uncommon. Given its
rarity, we had to recruit from multiple referral centers to
obtain sufficient numbers. Furthermore, the protocol for the
FOX study where we collected blood within 2 h of birth so
we could contemporaneously correlate circulating mRNA
findings with umbilical cord pH may be considered novel.
An important further strength is that we validated findings
in the FOX study in an independent preterm fetal growth re-
striction cohort from Europe.
One limitation is that we had anticipated we would ob-
tain a larger number of fetuses that were acidemic at birth
in the FOX cohort. The fact that only 22 of the cohort
with preterm fetal growth restriction were significantly
acidemic at birth (pH < 7.2) meant we were likely to be
underpowered to find significant hits using the RNA-seq
data. However, by examining the RT-PCR quantitative
data on the 13 genes that were differentially expressed
with preterm fetal growth restriction, we generated a
multi-marker test with an AUC of 0.72. This suggests that
it remains possible a circulating mRNA signature exists
that can identify fetal acidemia, but further development
of a clinical test would require larger studies so a cohort
of fetuses born acidemic is recruited in sufficient numbers
for adequately powered studies. While possible, this would
be a challenging cohort to collect.
We have provided robust evidence in three cohorts
that circulating mRNA signatures are altered where
there is placental insufficiency, severe placental dysfunc-
tion including fetal hypoxia, and even impending still-
birth. We hope it will generate interest for new studies
to further develop an mRNA signature that could help
clinicians identify which fetuses are truly acidemic in
utero and need urgent birth, compared to those who are
not compromised and may be left safely in utero to gain
gestation and advance fetal development. Such future
studies would need to identify a test that combines the
expression of different mRNAs that has strong perform-
ance characteristics for placental insufficiency, lock
down an algorithm, and validate the test in a prospective
validation study. Furthermore, these studies would also
need to demonstrate strong associations with important
clinical outcomes such as severe neonatal complications
and optimally, also neurodevelopmental outcomes. If de-
veloped, such a test could decrease stillbirths and im-
prove perinatal and long-term outcomes.
(See figure on previous page.)
Fig. 4 The association between circulating mRNAs in the maternal circulation and clinical parameters that reflect placental insufficiency. Those
with preterm fetal growth restriction in the EVERREST study were examined. Circulating levels of a EMP1 and b RCBTB2 and uterine artery blood
flow Pulsatility Index (PI), where >95th centile is a threshold clinical to suggest increased blood flow resistance that occurs with increased
placental insufficiency. c Circulating levels of EMP1 and the umbilical artery (UA), where > 95th PI is abnormally increased (also reflects placental
insufficiency). d Circulating levels of RCBTB2 and e NR4A2 and the middle cerebral artery (MCA), where < 5th PI is abnormal and suggests fetal
circulatory redistribution that occurs when fetuses are coping with placental insufficiency. f Circulating levels of EMP1 and g RCBTB2 at initial
recruitment grouped to whether the pregnancy was delivered preterm or progressed to term gestation (> 37 weeks’ gestation). *p < 0.05, **p <
0.01, ***p < 0.001. Error bars are mean ± SEM
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Fig. 5 The association between circulating mRNAs in maternal circulation and future stillbirth. a–c Expression levels of three circulating mRNAs
among women with a live pregnancy at the time of blood sampling but later had a stillbirth. These were the last bloods taken closest to demise.
d–f Serial blood samples taken from these same cases of stillbirth prior to fetal demise (one sample taken for two patients; two samples taken
across 5 and 14 days for two patients; three samples taken across 10 days for one patient, and 6 bloods taken across 36 days for one patient). Red
dotted line represents the median mRNA expression levels of the control group (the same controls as shown in a–c). These controls were healthy
ongoing pregnancies where bloods were taken at similar gestations. *p < 0.05, **p < 0.01, ***p < 0.001. Error bars are mean ± SEM
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of the postulated biological functions of the proteins encoded by the
five genes that were differentially regulated in the FOX cohort.
Supplementary Fig. S1. Expression of circulating mRNAs among
pregnancies with preterm fetal growth restriction in the FOX cohort. A-H
shows qRT-PCR expression of eight genes identified by RNA-seq, and
their respective receiver operating characteristic (AUC) curves. Controls
were ongoing pregnancies unaffected by growth restriction where
bloods were collected around the same gestational ages. **** p < 0.0001.
Error bars are mean ± SEM. Supplementary Fig. S2. Expression of five
circulating mRNAs among 16 women who had bloods taken just prior to
(Pre), and 24 h after (Post) an intramuscular injection of corticosteroid
(11.4 mg of betamethasone). These are the same five mRNAs as those
shown in Fig. 1 of the main manuscript. None were significantly different
after the injection of corticosteroids. Error bars are mean ± SEM. Supple-
mentary Fig. S3. Expression of eight circulating mRNAs among 16
women who had bloods taken just prior to (Pre), and 24 h after (Post) an
intramuscular injection of corticosteroid (11.4 mg of betamethasone).
These are the same eight mRNAs as those shown in supplementary Fig.
S1. ** p < 0.01, *** p < 0.001, **** p < 0.0001. Error bars are mean ± SEM.
Supplementary Fig. S4. Expression of the five circulating mRNAs in the
FOX cohort where the cases of preterm fetal growth restriction were split
according to whether there was co-existent preeclampsia, or not.
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